Otsuka Holdings Management

Management criteria checks 4/4

Otsuka Holdings' CEO is Tatsuo Higuchi, appointed in Jul 2008, has a tenure of 15.83 years. total yearly compensation is ¥280.00M, comprised of 55.7% salary and 44.3% bonuses, including company stock and options. directly owns 0.031% of the company’s shares, worth $7.04M. The average tenure of the management team and the board of directors is 2.3 years and 6.2 years respectively.

Key information

Tatsuo Higuchi

Chief executive officer

JP¥280.0m

Total compensation

CEO salary percentage	55.7%
CEO tenure	15.8yrs
CEO ownership	0.03%
Management average tenure	2.3yrs
Board average tenure	6.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Tatsuo Higuchi's remuneration changed compared to Otsuka Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	JP¥138b
Dec 31 2023	n/a	n/a	JP¥122b
Sep 30 2023	n/a	n/a	JP¥185b
Jun 30 2023	n/a	n/a	JP¥167b
Mar 31 2023	n/a	n/a	JP¥172b
Dec 31 2022	JP¥280m	JP¥156m	JP¥134b
Sep 30 2022	n/a	n/a	JP¥110b
Jun 30 2022	n/a	n/a	JP¥104b
Mar 31 2022	n/a	n/a	JP¥104b
Dec 31 2021	JP¥283m	JP¥156m	JP¥125b
Sep 30 2021	n/a	n/a	JP¥147b
Jun 30 2021	n/a	n/a	JP¥153b
Mar 31 2021	n/a	n/a	JP¥155b
Dec 31 2020	JP¥316m	JP¥156m	JP¥148b
Sep 30 2020	n/a	n/a	JP¥143b
Jun 30 2020	n/a	n/a	JP¥146b
Mar 31 2020	n/a	n/a	JP¥146b
Dec 31 2019	JP¥244m	JP¥156m	JP¥127b
Sep 30 2019	n/a	n/a	JP¥116b
Jun 30 2019	n/a	n/a	JP¥86b
Mar 31 2019	n/a	n/a	JP¥79b
Dec 31 2018	JP¥178m	JP¥156m	JP¥82b
Sep 30 2018	n/a	n/a	JP¥117b
Jun 30 2018	n/a	n/a	JP¥134b
Mar 31 2018	n/a	n/a	JP¥114b
Dec 31 2017	JP¥298m	JP¥157m	JP¥112b

Compensation vs Market: Tatsuo's total compensation ($USD1.78M) is below average for companies of similar size in the US market ($USD13.53M).

Compensation vs Earnings: Tatsuo's compensation has been consistent with company performance over the past year.

CEO

Tatsuo Higuchi (73 yo)

15.8yrs

Tenure

JP¥280,000,000

Compensation

Mr. Tatsuo Higuchi has been the President, Chief Executive Officer and Representative Director of Otsuka Holdings Co., Ltd. since July 2008. Mr. Higuchi has been the Chairman of Otsuka Pharmaceutical Co.,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tatsuo Higuchi	CEO, President & Representative Director	15.8yrs	JP¥280.00m	0.031% ¥ 7.0m
Makoto Inoue	COO & Representative Director	less than a year	JP¥154.00m	0.0088% ¥ 2.0m
Yoshiro Matsuo	Executive Deputy President & Executive Director	2.2yrs	JP¥128.00m	0.012% ¥ 2.7m
Masayuki Kobayashi	Executive Director	7.2yrs	JP¥138.00m	0.014% ¥ 3.1m
Yuko Makino	CFO & Executive Director	6.2yrs	no data	0.0040% ¥ 915.4k
Akiko Ryu	Senior VP & Director of Human Resource Planning Department	2.3yrs	no data	no data
Noriko Tojo	Executive Director	6.2yrs	JP¥104.00m	0.011% ¥ 2.5m
Shuichi Takagi	Executive Director	5.2yrs	no data	0.0053% ¥ 1.2m
Chiaki Sakurai	Senior Vice President of Nutraceutical Business	2.3yrs	no data	no data
Shigeko Takahashi	Senior VP and GM of Nutraceutical Business	2.3yrs	no data	no data
Manabu Kawata	Senior Vice President of Business Development Department	2.3yrs	no data	no data
Toshihiro Tokumoto	Senior Vice President of Nutraceutical Business	2.3yrs	no data	no data

2.3yrs

Average Tenure

62yo

Average Age

Experienced Management: OTSK.Y's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Tatsuo Higuchi	CEO, President & Representative Director	15.8yrs	JP¥280.00m	0.031% ¥ 7.0m
Makoto Inoue	COO & Representative Director	4.2yrs	JP¥154.00m	0.0088% ¥ 2.0m
Yoshiro Matsuo	Executive Deputy President & Executive Director	no data	JP¥128.00m	0.012% ¥ 2.7m
Masayuki Kobayashi	Executive Director	7.2yrs	JP¥138.00m	0.014% ¥ 3.1m
Yuko Makino	CFO & Executive Director	6.2yrs	no data	0.0040% ¥ 915.4k
Noriko Tojo	Executive Director	6.2yrs	JP¥104.00m	0.011% ¥ 2.5m
Shuichi Takagi	Executive Director	5.2yrs	no data	0.0053% ¥ 1.2m
Ichiro Otsuka	Chairman	15.8yrs	JP¥240.00m	1.45% ¥ 327.3m
Yukio Matsutani	Independent Outside Director	8.2yrs	no data	no data
Ko Sekiguchi	Independent Outside Director	6.2yrs	no data	no data
Yozo Toba	Chairman of Audit & Supervisory Board Member	6.2yrs	no data	0.0013% ¥ 291.6k
Yoshihisa Aoki	Independent Outside Director	5.2yrs	no data	no data

6.2yrs

Average Tenure

64yo

Average Age

Experienced Board: OTSK.Y's board of directors are considered experienced (6.2 years average tenure).

Otsuka Holdings Management

Management criteria checks 4/4

Key information

Recent management updates

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2021

Recent updates

Otsuka Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024

Otsuka Holdings Co., Ltd. Revises Dividend for the Full Year Ending December 31, 2023, Payable on March 29 , 2024

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

Otsuka Holdings Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year 2023

Otsuka Pharmaceutical Co., Ltd. Announces Positive Results of Phase III Trial in Japan Showing Reduced Agitation in Patients with Alzheimer's Dia Treated with Brexpiprazole

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Jul 31, 2023

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Otsuka Holdings Co., Ltd. Provides Dividend Guidance for Fiscal Year Ending 2023

Otsuka Pharmaceutical Co., Ltd. (Otsuka) Files an Application in Japan for an Additional Indication for Rexulti

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Otsuka Medical Devices Co., Ltd. and Recor Medical, Inc. Announce Submission of Application for Pre-Market Approval of the Paradise uRDN to the U.S. FDA

Otsuka Holdings Co., Ltd. Revises Consolidated earnings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earrings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month by Otsuka America Pharmaceutical, Inc

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2022 Results on Jul 29, 2022

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter and Full Year of Fiscal Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year 2021

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2021

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2020 Results on Feb 12, 2021

Otsuka Holdings Co., Ltd. to Report Q3, 2020 Results on Nov 13, 2020

Otsuka Holdings Co., Ltd. to Report Q2, 2020 Results on Aug 07, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age